Pioneers in patient-based
drug discovery

From Patient to drug:
Human Patient derived drug candidates for next generation medicines.

At Ksilink, we design and apply patient-based cellular disease models and other complex cellular systems applicable for large-scale phenotypic screening to support partners, customers and our in house programs. Our proprietary drug discovery engine applies unique AI-boosted cellular profiling technologies to identify druggable targets and develop the most efficient compounds for novel treatment options.

Given the rising costs of drug discovery combined with high failure rates in late-stage clinical development, our proprietary pipeline of patient-based drug discovery programs aims at derisking next generation medicine for neurologic diseases with high medical need.

In addition, we also engage with partners and customers to develop tailor made solutions based on our unique capability in handling a broad range of complex cellular systems. Based on our expertise in microscope based read out systems, we develop assays systems, solutions for high throughput phenotypic screening approaches or complete package solutions from assay development up to target identification for relevant hit molecules.